Article thumbnail

Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection

By Sylvia Stemberger, Angelika Jamnig, Nadia Stefanova, Günter Lepperdinger, Markus Reindl and Gregor K. Wenning
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3097217
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). Adult bone marrow stromal cells differentiate into neural cells in vitro.
  2. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential.
  3. (2005). Alterations of Tlymphocyte populations in Parkinson disease.
  4. (2008). Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.
  5. (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation.
  6. (1994). Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
  7. (2007). Concise review: mesenchymal stem/ multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views.
  8. (2005). Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
  9. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs.
  10. (1998). Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies.
  11. (2007). From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells.
  12. (2005). Gait dynamics in mouse models of Parkinson’s disease and Huntington’s disease.
  13. (2009). Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy.
  14. (1989). Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).
  15. (2002). Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.
  16. (1996). If you assume, you can make an ass out of u and me’: a decade of the disector for stereological counting of particles in 3D space.
  17. (2009). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.
  18. (2007). Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson’s disease.
  19. (2004). Loss of SHP-1 phosphatase alters cytokine expression in the mouse hindbrain following cochlear ablation.
  20. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues.
  21. (2006). Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia.
  22. (2008). Mesenchymal stem cells from adult bone marrow.
  23. (2008). Mesenchymal stem cells in health and disease.
  24. (2007). Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy.
  25. (2004). Microglial activation parallels system degeneration in multiple system atrophy.
  26. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
  27. (2005). Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration.
  28. (1999). Multilineage potential of adult human mesenchymal stem cells.
  29. (2008). Multiple system atrophy: a primary oligodendrogliopathy.
  30. (2009). Multiple system atrophy: an update.
  31. (2010). Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model.
  32. (2005). Neural transdifferentiation of mesenchymal stem cells–a critical review.
  33. (2005). Neuro-glial differentiation of human bone marrow stem cells in vitro.
  34. (2009). Neuroinflammation in Parkinson’s disease: a target for neuroprotection?
  35. (2005). Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
  36. (2003). Neuropathological spectrum of synucleinopathies.
  37. (2008). Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.
  38. (2010). Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy-parkinsonism. Cell Transplant;ct0169park [pii];10.
  39. (2009). Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
  40. (2001). Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo.
  41. (2010). Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease.
  42. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
  43. (2005). Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.
  44. (2006). Pathology and genetics of multiple system atrophy: an approach to determining genetic susceptibility spectrum.
  45. (2009). Recent developments in multiple system atrophy.
  46. (2010). Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol.
  47. (1996). Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
  48. (2009). SNCA variants are associated with increased risk for multiple system atrophy.
  49. (2007). Stem cell transplantation: the lung barrier.
  50. (2009). Striatal transplantation for multiple system atrophy–are grafts affected by alpha-synucleinopathy?
  51. (2009). Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response.
  52. (2010). Survival and immunogenicity of mesenchymal stem cells from the green fluorescent protein transgenic rat in the adult rat brain.
  53. (2010). Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.
  54. (2008). Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.
  55. (1998). The definition of multiple system atrophy: a review of recent developments.
  56. (1991). Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator.